| Description |
Nemadipine-A is a specific inhibitor of the EGL-19 L-type Ca2+ channel[1]. Nemadipine-A, a cell-permeable L-type calcium channel inhibitor, sensitizes TRAIL-resistant cancer cells to this ligand[2].
|
| Related Catalog |
|
| In Vitro |
Nemadipine-A is a specific and highly effective inhibitor of EGL-19. Nemadipine-A (µM) is sufficient to abolish the enhanced level of paralysis observed in egl-19(ad695); crIs4 mutants[1]. Nemadipine-A strongly potentiates TRAIL-induced apoptosis in TRAIL-resistant lung cancer cells via the down-regulation of the anti-apoptotic protein survivin[2]. Nemadipine-A sensitizes H1299 lung cancer cells towards TRAIL-induced cytotoxicity[2]. Combination of Nemadipine-A (20 μM) with TRAIL (20 ng/mL) induces caspase-mediated apoptotic cell death[2]. Cell Viability Assay[2] Cell Line: H1299 lung adenocarcinoma cells Concentration: 0, 5, 10, 20, and 30 μM Incubation Time: 8 hours Result: H1299 cells were resistant to the apoptotic effects of TRAIL, but the co-administration of Nemadipine-A and TRAIL in these cells resulted in notably increased cytotoxicity in a dose-dependent manner. Western Blot Analysis[2] Cell Line: H1299 cells Concentration: 20 μM Incubation Time: 8 hours Result: Co-treated with TRAIL and Nemadipine-A (T/N; 20 ng/mL and 20 μM respectively) induced cell death in H1299 cells.
|
| References |
[1]. Peter I Joyce, et al. The atypical calpains: evolutionary analyses and roles in Caenorhabditis elegans cellular. PLoS Genet. 2012;8(3):e1002602.degeneration [2]. Seong Ho Park, et al. Down-Regulation of Survivin by Nemadipine-A Sensitizes Cancer Cells to TRAIL-Induced Apoptosis. Biomol Ther (Seoul). 2013 Jan;21(1):29-34.
|
